Navigation Links
Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract
Date:7/6/2010

BEIJING, July 6 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, announced today that it has signed a contract to sell 10,000 oxygen-chip units to Beijing C&D Co., Ltd. for RMB11 million (about $1.58 million).

The patented oxygen-chip, jointly developed by Dehaier and the University of Science and Technology Beijing in 2008, is the core part of an oxygen concentrator. The oxygen concentrator's small size and simplified procedures for oxygen production ensure that oxygen density reaches 93%. Such high concentrations of oxygen are important for use by patients with cardiovascular disease, respiratory diseases such as chronic obstructive pulmonary disease, and geriatric patients. Dehaier oxygen-chip production technology is widely regarded as an industry leader.

CEO Ping Chen said, "This sales contract substantiates the strong competitive advantage enjoyed by our home oxygen therapy products and their influence in the market. This gives us confidence about our ability to expand our sales to the overseas home oxygen therapy market. With our proprietary oxygen-chip, any manufacturing factory will be able to produce state-of-the- art oxygen concentrators, which can be used to create standard oxygen density with pressure supply devices."

About Beijing C&D Co., Ltd.

As a wholly owned subsidiary of Xiamen C&D Inc., Beijing C&D Co., Ltd. provides importing agency service and commercial service in the field of industrial instrument and machinery, medical devices, industrial chemicals and laboratory instruments. More information may be found at: http://www.chinacnd.com/web/home .

About Dehaier Medical Systems Ltd.

Dehaier Medical Systems is an emerging leader in the development, assembly, marketing and sale of medical products in China, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded products from third party components. The company also distributes products designed and manufactured by other companies including medical devices and respiratory and oxygen homecare products from IMD (Italy), Welch Allyn (USA), Penlon (UK), HEYER (Germany), Timesco (UK), ResMed (Australia) and JMS (Japan). Dehaier's technology is based on two patents, five pending patents and proprietary technology. More information may be found at http://www.chinadhr.com .

Information for investors, including an investment profile about Dehaier is available at http://www.hawkassociates.com/profile/dhrm.cfm . An online investor kit including press releases, current price quotes, stock charts and other valuable information for investors is available at http://www.hawkassociates.com .

Forward-looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

    For more information, please contact:

    Investor contact:
     Hawk Associates
     Julie Marshall or Frank Hawkins
     Tel:   +1-305-451-1888
     Email: dehaier@hawkassociates.com


'/>"/>
SOURCE Dehaier Medical Systems Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dehaier Medical Systems Continues Product Line Expansion. Signs Exclusive Distribution Agreement with HEYER Medical for Respiratory Products in China
2. Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China
3. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
4. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
5. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
6. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
7. BioMS Medical announces its intention to renew a normal course issuer bid
8. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
9. ATS Medical Expands Open Pivot Heart Valve Offerings
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. Globus Medical Announces Record 2nd Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... Prairie, WI (PRWEB) , ... June 23, 2016 ... ... consultancy focused on quality, regulatory and technical consulting, provides a free webinar ... is presented on July 13, 2016 at 12pm CT at no charge. , ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
Breaking Biology News(10 mins):